NEWS HIGHLIGHTSMedia Articles Related to Urso 250 (Ursodiol)
Primary Biliary Cirrhosis
Source: MedicineNet Antimitochondrial Antibodies Specialty [2005.09.17]
Title: Primary Biliary Cirrhosis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 9/17/2005 12:00:00 AM
Published Studies Related to Urso 250 (Ursodiol)
Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a
randomized cross-over trial. [2012]
To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) with oral
solubilized formula in amyotrophic lateral sclerosis (ALS) patients, patients
with probable or definite ALS were randomized to receive oral solubilized UDCA
(3.5 g/140 mL/day) or placebo for 3 months after a run-in period of 1 month and
switched to receive the other treatment for 3 months after a wash-out period of 1
month...
Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. [2011.09]
BACKGROUND & AIMS: The combination of ursodeoxycholic acid (UDCA), colchicine, and methotrexate (MTX) is effective therapy for a subset of patients with primary biliary cirrhosis (PBC) who do not respond to UDCA. However, the durability of the response is unclear. We investigated whether the response to combination therapy was durable... CONCLUSIONS: Treatment with the combination of UDCA and MTX or UDCA and colchicine led to sustained clinical remission in a subset of patients with PBC. The response to the combination of UDCA and MTX appeared to be more durable than to UDCA and colchicine. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011.09]
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC... CONCLUSIONS: Long-term use of high-dose UDCA is associated with an increased risk of colorectal neoplasia in patients with UC and PSC.
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. [2011.05]
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with increased morbidity and mortality. Ursodeoxycholic acid (UDCA) may have antioxidant, anti-inflammatory, and antifibrotic properties and may reduce liver injury in NASH. To date, no studies have assessed the efficacy and safety of high-dose UDCA (HD-UDCA) in patients with NASH... CONCLUSIONS: Treatment with HD-UDCA was safe, improved aminotransferase levels, serum fibrosis markers, and selected metabolic parameters. Studies with histologic end points are warranted. Copyright (c) 2011. Published by Elsevier B.V.
Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. [2011]
Bile acids have recently been identified as major integrators of hepatic fatty acid and triglyceride metabolism. We explored potential mechanism(s) of action of ursodeoxycholic acid (20 mg/kg/day in 3 weeks) in 40 morbidly obese patients (mean BMI >40 kg/m(2)) with suggested fatty liver disease awaiting bariatric surgery.
Clinical Trials Related to Urso 250 (Ursodiol)
Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates [Recruiting]
The purpose of this study is to determine whether ursodiol is effective in the treatment of
parenteral nutrition associated cholestasis in neonates.
The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice [Not yet recruiting]
ABSTRACT:
In patients with obstructive jaundice, multi-organ dysfunction may develop. The aim of this
study is to evaluate the effect of ursodeoxycholic acid on liver functional restoration on
patients with obstructive jaundice after surgical or endoscopic treatment.
Patients with obstructive jaundice will be divided into two groups: (A) test group in which
will be administered ursodeoxycholic acid twenty-four hours after endoscopic or surgical
procedure and will last fourteen days, and (B) control group.
Serum-testing will include determination of bilirubin, alanine transaminase, aspartate
transaminase, gama-glutamyl transpeptidase, alkaline phosphatase, albumin, and cholesterol
levels. These parameters will be determined one day prior endoscopic or surgical procedure,
and on the third, fifth, seventh, tenth, twelfth and fourteenth days after endoscopic or
surgical intervention.
Our hypothesis is that patients with obstructive jaundice under treatment with
ursodeoxycholic acid will have better outcome than patients in control group.
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia [Recruiting]
This phase II trial is studying how well ursodiol works in treating patients with Barrett
esophagus or low-grade dysplasia. Chemoprevention is the use of certain drugs to keep cancer
from forming. The use of ursodiol may in patients with Barrett esophagus or low-grade
dysplasia
Trial of High-Dose Urso in Primary Sclerosing Cholangitis [Completed]
This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for
patients with primary sclerosing cholangitis (PSC). The average duration of follow-up will
be approximately five years with important clinical endpoints such as death, eligibility for
liver transplanation, changes in histology and cholangiogram as well as liver biochemistries
and quality of life data collected.
Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC) [Recruiting]
The study is aimed to compare the efficacy and tolerability of a combination therapy with
ursodeoxycholic acid (12-16 mg/kg body weight (BW)/d) plus budesonide (9 mg/d) vs.
ursodeoxycholic acid (12-16 mg/kg BW/d) plus placebo in the treatment of PBC. Depending on
ALT values 6 mg/d budesonide are allowed. The study population will be patients with PBC at
risk for disease progression. It is assumed that the combination therapy will result in a
decrease of treatment failures after 3 years of treatment.
Reports of Suspected Urso 250 (Ursodiol) Side Effects
Sudden Cardiac Death (4),
Confusional State (1),
Jaundice (1),
Productive Cough (1),
Hepatic Function Abnormal (1),
Hypoglycaemia (1),
Rales (1),
Pyrexia (1),
Hypokalaemia (1),
Liver Disorder (1), more >>
|
